HC Wainwright Has Positive Outlook for CGTX Q3 Earnings

Cognition Therapeutics, Inc. (NASDAQ:CGTX) – Stock analysts at HC Wainwright boosted their Q3 2026 earnings per share estimates for shares of Cognition Therapeutics in a report issued on Thursday, August 13th. HC Wainwright analyst R. Selvaraju now anticipates that the company will post earnings of ($0.06) per share for the quarter, up from their previous estimate of ($0.07). HC Wainwright currently has a “Buy” rating on the stock. The consensus estimate for Cognition Therapeutics’ current full-year earnings is ($0.30) per share. HC Wainwright also issued estimates for Cognition Therapeutics’ Q4 2026 earnings at ($0.05) EPS and FY2026 earnings at ($0.20) EPS.

A number of other analysts have also recently weighed in on CGTX. Wall Street Zen cut shares of Cognition Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday. Weiss Ratings restated a “sell (d-)” rating on shares of Cognition Therapeutics in a research note on Wednesday, June 24th. Three investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $3.33.

Cognition Therapeutics Trading Up 1.0%

Shares of CGTX opened at $1.02 on Monday. The company’s 50 day simple moving average is $1.10 and its 200-day simple moving average is $1.10. The firm has a market cap of $96.99 million, a PE ratio of -6.00 and a beta of 1.78. Cognition Therapeutics has a 12-month low of $0.55 and a 12-month high of $3.83.

Cognition Therapeutics (NASDAQ:CGTX) last released its quarterly earnings results on Thursday, August 6th. The company reported ($0.04) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.06) by $0.02.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of CGTX. Northwestern Mutual Wealth Management Co. raised its stake in shares of Cognition Therapeutics by 11,695.3% during the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 2,060,282 shares of the company’s stock worth $2,781,000 after purchasing an additional 2,042,815 shares during the last quarter. Vanguard Group Inc. lifted its holdings in shares of Cognition Therapeutics by 105.6% during the third quarter. Vanguard Group Inc. now owns 2,681,613 shares of the company’s stock worth $3,620,000 after purchasing an additional 1,377,263 shares during the period. BlackRock Inc. purchased a new position in Cognition Therapeutics in the 2nd quarter valued at $1,451,000. Acadian Asset Management LLC grew its position in Cognition Therapeutics by 814.1% in the 1st quarter. Acadian Asset Management LLC now owns 1,007,586 shares of the company’s stock valued at $422,000 after buying an additional 897,353 shares during the last quarter. Finally, Millennium Management LLC acquired a new position in Cognition Therapeutics in the 3rd quarter valued at $757,000. Institutional investors and hedge funds own 43.35% of the company’s stock.

Cognition Therapeutics Company Profile

Cognition Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing disease-modifying therapies for neurodegenerative disorders, with an emphasis on Alzheimer’s disease. The company’s lead investigational candidate, CT1812, is an oral small molecule that antagonizes the sigma-2 receptor complex to protect synapses from amyloid-beta oligomer toxicity. By targeting a novel mechanism of action, Cognition Therapeutics aims to slow or reverse cognitive decline in patients living with Alzheimer’s disease.

CT1812 has successfully completed Phase 1 safety studies and preliminary Phase 2a trials, and is currently being evaluated in multiple Phase 2 clinical studies across North America and Europe in patients with mild-to-moderate Alzheimer’s disease.